A new wave of product liability against drug makers? Tomorrow the Supreme Court decides

Article Highlights

  • Mutual Pharmaceutical Co. v. Bartlett turns on a novel tort concept that’s being advanced by the trial bar called “design defect” claims

    Tweet This

  • The “design defect” legal theory puts state juries in the position of second-guessing FDA’s judgment in approving new drugs

    Tweet This

  • Because the legal theory undermines the heart of FDA’s mission, the Obama Administration has filed a brief siding against the plaintiffs

    Tweet This

 

On the Op Ed page of today’s Politico.com, I comment on a case that’s being heard before the Supreme Court tomorrow. It concerns drug makers and the issue of federal pre-emption of state tort claims. And it has big implications for the industry.

The case, Mutual Pharmaceutical Co. v. Bartlett, turns on novel tort concept that’s being advanced by the trial bar called “design defect” claims.

In a nutshell, the allegation in a “design defect” claim is that a drug product was flawed from the very beginning – in other words, the drug’s risks always outweighed its benefits. In short, the plaintiffs in these cases are arguing that the drug should never have been marketed in a particular state. Not to mention, approved by the Food and Drug Administration in the first place.

If it sounds like the “design defect” legal theory puts state juries in the position of second-guessing FDA’s judgment in approving new drugs, that’s precisely the point.

Although this particular case involves a generic drug maker, the same claims are going to be filed against branded drug makers. If the trial bar is successful in the current case, this could be the next big area of product liability against drug makers.

Because the legal theory undermines the very heart of FDA’s mission and its mandate to weigh the risk and benefits of medical products, the Obama Administration has filed a brief in the case siding against the plaintiffs. This has put the Obama Administration on the record opposing an area of product liability and supporting the drug maker’s argument of federal preemption from these suits.

But the company involved in the current case is a generic drug firm. And before the branded drug makers think that brief puts the Administration on their side, too, they should read that brief closely. It goes to great lengths to provide a roadmap on how trial attorneys could mend future pleadings to satisfy the Administration’s concerns while advancing their novel tort theory against the branded drug industry.

 

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Scott
Gottlieb

What's new on AEI

Love people, not pleasure
image Oval Office lacks resolve on Ukraine
image Middle East Morass: A public opinion rundown of Iraq, Iran, and more
image Verizon's Inspire Her Mind ad and the facts they didn't tell you
AEI on Facebook
Events Calendar
  • 21
    MON
  • 22
    TUE
  • 23
    WED
  • 24
    THU
  • 25
    FRI
Monday, July 21, 2014 | 9:15 a.m. – 11:30 a.m.
Closing the gaps in health outcomes: Alternative paths forward

Please join us for a broader exploration of targeted interventions that provide real promise for reducing health disparities, limiting or delaying the onset of chronic health conditions, and improving the performance of the US health care system.

Monday, July 21, 2014 | 4:00 p.m. – 5:30 p.m.
Comprehending comprehensive universities

Join us for a panel discussion that seeks to comprehend the comprehensives and to determine the role these schools play in the nation’s college completion agenda.

Tuesday, July 22, 2014 | 8:50 a.m. – 12:00 p.m.
Who governs the Internet? A conversation on securing the multistakeholder process

Please join AEI’s Center for Internet, Communications, and Technology Policy for a conference to address key steps we can take, as members of the global community, to maintain a free Internet.

Event Registration is Closed
Thursday, July 24, 2014 | 9:00 a.m. – 10:00 a.m.
Expanding opportunity in America: A conversation with House Budget Committee Chairman Paul Ryan

Please join us as House Budget Committee Chairman Paul Ryan (R-WI) unveils a new set of policy reforms aimed at reducing poverty and increasing upward mobility throughout America.

Thursday, July 24, 2014 | 6:00 p.m. – 7:15 p.m.
Is it time to end the Export-Import Bank?

We welcome you to join us at AEI as POLITICO’s Ben White moderates a lively debate between Tim Carney, one of the bank’s fiercest critics, and Tony Fratto, one of the agency’s staunchest defenders.

No events scheduled this day.
No events scheduled today.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.